The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies, including an immunomodulatory agent,…
Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here. Alternatively known under the branded name “Revlimid”, lenalidomide is a…
Today Myeloma Patients Europe (MPE) published our 2021: Year in Review, a snapshot of the major accomplishments from the past year. In 2021, MPE launched two projects that will provide distinct and indispensable resources…
Myeloma Patients Europe (MPE) has today relaunched the Myeloma Access Atlas, an online platform designed to provide myeloma and AL amyloidosis patient advocates with the information and tools needed to work effectively on access issues.…
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete…